Based on: Chronic Kidney Disease — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 57 candidate interventions for chronic kidney disease that are either approved medicines or have at least one registered clinical trial, built on 10 druggable gene targets, with 14 recent trials on ClinicalTrials.gov. 8 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Soluble Ferric Pyrophosphate — 5 registered trials · investigational · NCT01894906 NCT00548249
- Epoetin alfa — 2 registered trials · approved medicine · NCT00090753 NCT00307814
- calcium acetate — 1 registered trial · approved medicine · NCT00211978
- Darbepoetin alfa — 1 registered trial · approved medicine · NCT00090753
- Epoetin beta — 1 registered trial · approved medicine · NCT00090753
- Methoxy Polyethylene Glycol-Epoetin Beta — 1 registered trial · approved medicine · NCT00090753
- Assessment guiding surgery and puncture for AVF — 1 registered trial · investigational · NCT02880761
- Atorvastatin — 1 registered trial · investigational · NCT01257009
- ATSM + Health Coach — 1 registered trial · investigational · NCT01530958
- Calcitriol - CKD — 1 registered trial · investigational · NCT01222234
- Cholecalciferol - CKD — 1 registered trial · investigational · NCT01222234
- Cholecalciferol - non-CKD — 1 registered trial · investigational · NCT01222234
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in chronic kidney disease and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: ACE, AGTR1, C5, CFH, COL4A5, EDNRA, NFE2L2, NR3C2, SLC5A2, TGFB1.
Which trials are registered?
- Physical Activity in CKD NCT06624358 · Recruiting · Phase NA · started 2025-09-30
- A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event NCT07783802 · Recruiting · Phase PHASE2 · started 2026-08-27
- Comparing The Effect Of Empagliflozin With Dapagliflozin In Reducing Proteinuria In Diabetic Patients With Chronic Kidney Disease With eGFR More Than 45ml/Min/1.73m² NCT07866235 · Completed · Phase NA · started 2023-10-11
- Biomarkers, Abdominal Muscle, and Frailty in CKD NCT07854275 · Completed · started 2025-01-15
- A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease NCT04671771 · Recruiting · Phase NA · started 2020-12-03
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) NCT07241390 · Recruiting · Phase PHASE3 · started 2025-12-01
- An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea NCT07232537 · Active Not Recruiting · started 2025-11-20
- Evaluation of IGRA, Symptoms and Chest Radiograph for Subclinical TB Detection in ESRD and KT NCT06700876 · Active Not Recruiting · started 2024-08-06
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) NCT06383390 · Active Not Recruiting · Phase PHASE3 · started 2024-04-30
- The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD NCT05374291 · Active Not Recruiting · Phase PHASE3 · started 2022-11-08
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.